Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia
Astaxanthin has been reported to improve dyslipidemia and metabolic syndrome in animals, but such effects in humans are not well known. Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18 mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum trigly...
Saved in:
Published in | Atherosclerosis Vol. 209; no. 2; pp. 520 - 523 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier Ireland Ltd
01.04.2010
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Astaxanthin has been reported to improve dyslipidemia and metabolic syndrome in animals, but such effects in humans are not well known.
Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18
mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum triglyceride of 120–200
mg/dl and without diabetes and hypertension, aged 25–60 years.
In before and after tests, body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglyceride decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18
mg/day doses significantly reduced triglyceride, and 6 and 12
mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18
mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI.
This first-ever randomized, placebo-controlled human study suggests that astaxanthin consumption ameliorates triglyceride and HDL-cholesterol in correlation with increased adiponectin in humans. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 0021-9150 1879-1484 1879-1484 |
DOI: | 10.1016/j.atherosclerosis.2009.10.012 |